
    
      Phase III, multicenter, multinational, double-blind, double-dummy, randomised, 2-arm
      parallel-group, 3-month study in patients with stable COPD.

      Comparison in terms of efficacy and safety of the two formulations of formoterol administered
      as 24Âµg/day in a bid regimen
    
  